What Happened?

Shares of clinical research company Fortrea Holdings (NASDAQ: FTRE) jumped 5.7% in the morning session after an analyst at Mizuho raised the company's price target. Analyst Ann Hynes reaffirmed a neutral stance on Fortrea Holdings but increased the price target to $13.00 from a previous $11.00. 

This move marked an 18.18% increase in the analyst's valuation of the stock. While the overall rating remained unchanged, the higher price target suggested a more optimistic outlook on the company's future stock performance from the analyst's perspective.

After the initial pop the shares cooled down to $16.90, up 4.4% from previous close.

Is now the time to buy Fortrea? Access our full analysis report here.

What Is The Market Telling Us

Fortrea’s shares are extremely volatile and have had 69 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 7 days ago when the stock gained 6.2% on the news that Citigroup upgraded the stock's rating to Buy from Neutral and significantly raised its price target. The analyst firm increased its price target by 75%, from $12.00 to $21.00. This positive shift reflected the firm's renewed confidence in Fortrea Holdings' market performance and future prospects, according to the analyst report.

Fortrea is down 9.4% since the beginning of the year, and at $16.90 per share, it is trading 14.4% below its 52-week high of $19.73 from January 2025. Investors who bought $1,000 worth of Fortrea’s shares at the IPO in June 2023 would now be looking at an investment worth $561.30.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.